Global Metabolic Syndrome Therapeutics Pipeline Review 2014 - Analysis of 14 Companies & 33 Drug Profiles
M2 - Mon Apr 28, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vtpws3/metabolic) has announced the addition of the "Metabolic Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metabolic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metabolic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metabolic Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metabolic Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Ildong Pharmaceutical Co., Ltd. - Chipscreen Biosciences Ltd - Abeille Pharmaceuticals, Inc. - Cortendo Invest AB - Spherix Incorporated - Ache Laboratorios Farmaceuticos S/A - Indus Biotech Private Limited - Cardax Pharmaceuticals, Inc. - VivaCell Biotechnology Espana S.L. - Poxel SA - Shanghai Pharmaceuticals Holding Co Ltd - Lead Discovery Center GmbH - MI.TO. Technology S.r.L. Drug Profiles - CS-038 - ACH-09 - MBX-8025 - chloroquine - eplerenone - SPX-10624258 - MB-12066 - AB-3001 - CDX-085 - CDE-001 - GQ-16 - Next Generation Cortisol Inhibitor - ND-630 - Drug Targeting AMPD2 - KH-064 - Metabolic Syndrome Program - Metabolic Syndrome Program - Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Small Molecules for Inflammatory Diseases - Myonectin - ID-2244 - ZLN-024 - C-24 - Drug Targeting Farnesoid X Receptor - Apoptosis Inhibitor Of Macrophages - Small Molecule for Cardiovascular And Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drugs Targeting Acetyl-CoA Carboxylase - 11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Targeting SIRT For more information visit http://www.researchandmarkets.com/research/vtpws3/metabolic